Correlation between cardiac remodelling, function, and myocardial contractility in rat hearts 5 weeks after myocardial infarction.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 9564549)

Published in Can J Physiol Pharmacol on January 01, 1998

Authors

H Gosselin1, X Qi, J L Rouleau

Author Affiliations

1: Department of Medicine, Institut de cardiologie de Montréal, QC, Canada.

Articles citing this

Fibrous scaffolds for building hearts and heart parts. Adv Drug Deliv Rev (2015) 0.78

Articles by these authors

(truncated to the top 100)

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76

Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62

Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05

Coupling of a signal response domain in I kappa B alpha to multiple pathways for NF-kappa B activation. Mol Cell Biol (1995) 5.32

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26

Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13

Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation (1994) 2.74

Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72

Waist-to-height ratio is the best indicator for undiagnosed type 2 diabetes. Diabet Med (2013) 2.31

N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation (1994) 2.05

Comparison and integration of four barley genetic maps. Genome (1996) 2.03

Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation (1997) 2.01

Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and Ventricular Enlargement. Circulation (1997) 1.96

Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med (2001) 1.93

Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J (2000) 1.88

Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int (2008) 1.86

Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J (1999) 1.76

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol (1998) 1.67

Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation (1994) 1.67

Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol (1990) 1.66

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation (1998) 1.63

Induction of primordial germ cells from murine epiblasts by synergistic action of BMP4 and BMP8B signaling pathways. Proc Natl Acad Sci U S A (2001) 1.56

Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study. Circulation (1982) 1.54

Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J (1998) 1.52

Bronchial hyperresponsiveness to inhaled methacholine in subjects with chronic left heart failure at a time of exacerbation and after increasing diuretic therapy. Chest (1989) 1.52

Performance of a modified rabbit model of abdominal aortic aneurysm induced by topical application of porcine elastase: 5-month follow-up study. Eur J Vasc Endovasc Surg (2012) 1.52

Prognosis evaluation in alpha-fetoprotein negative hepatocellular carcinoma after hepatectomy: comparison of five staging systems. Eur J Surg Oncol (2010) 1.49

The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol (2003) 1.49

Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation (1998) 1.45

Tyrosine phosphorylation of mitogen-activated protein kinases is necessary for activation of murine macrophages by natural and synthetic bacterial products. J Exp Med (1993) 1.44

Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. Ann Intern Med (2001) 1.39

Potential metabolite markers of schizophrenia. Mol Psychiatry (2011) 1.35

Basal phosphorylation of the PEST domain in the I(kappa)B(beta) regulates its functional interaction with the c-rel proto-oncogene product. Mol Cell Biol (1996) 1.33

Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol (1997) 1.33

Case-control study of risk factors for human infection with influenza A(H7N9) virus in Jiangsu Province, China, 2013. Euro Surveill (2013) 1.32

Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J Mol Biol (2008) 1.30

A new class of oxidosqualene cyclases directs synthesis of antimicrobial phytoprotectants in monocots. Proc Natl Acad Sci U S A (2001) 1.27

Emergence of a new GII.17 norovirus variant in patients with acute gastroenteritis in Jiangsu, China, September 2014 to March 2015. Euro Surveill (2015) 1.26

Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. Circulation (1995) 1.26

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23

Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog. Circ Res (1991) 1.22

Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol (2001) 1.21

Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res (1994) 1.19

Effect of phosphorylation on activities of Rap1A to interact with Raf-1 and to suppress Ras-dependent Raf-1 activation. J Biol Chem (1999) 1.18

Genetic tuning of the novel avian influenza A(H7N9) virus during interspecies transmission, China, 2013. Euro Surveill (2014) 1.16

Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int (1986) 1.16

Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol (1997) 1.14

Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages. J Immunol (1993) 1.14

Assessment of psychosocial functioning of patients with sickle cell disease. South Med J (1988) 1.12

Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis. Am Heart J (2001) 1.09

Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation (1997) 1.08

Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A (1998) 1.07

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J (2000) 1.06

A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis (2007) 1.05

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant (2009) 1.05

Broadband nonlinear optical response in multi-layer black phosphorus: an emerging infrared and mid-infrared optical material. Opt Express (2015) 1.05

Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction. Am J Cardiol (1997) 1.04

Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthalmol (1999) 1.04

The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins. Peptides (2000) 1.04

Age and gender differences in excitation-contraction coupling of the rat ventricle. J Physiol (1998) 1.04

Proteolytic processing patterns of prosaposin in insect and mammalian cells. J Biol Chem (1996) 1.03

The effects of the Chinese medicine ZiBu PiYin recipe on the hippocampus in a rat model of diabetes-associated cognitive decline: a proteomic analysis. Diabetologia (2011) 1.03

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J (2000) 1.02

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation (1997) 1.02

Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation (1997) 1.01

Verapamil suppresses atherosclerosis in cholesterol-fed rabbits. J Am Coll Cardiol (1983) 1.01

Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology (1999) 1.01

Analysis of transcripts that are differentially expressed in three sectors of the rice root system under water deficit. Mol Genet Genomics (2004) 1.00

Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med (1988) 0.99

Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. Circulation (1985) 0.99

Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol (1999) 0.96

Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: importance of initial plasma renin activity. Circulation (1986) 0.96

Decreased coronary sinus oxygen content: a predictor of adverse prognosis in patients with severe congestive heart failure. J Am Coll Cardiol (1991) 0.96

Long-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol (1994) 0.96

Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol (1984) 0.96

Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathy. Am Heart J (1988) 0.95

Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation (1992) 0.94

Mutation in Bmp7 exacerbates the phenotype of Bmp8a mutants in spermatogenesis and epididymis. Dev Biol (2001) 0.93

Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. Am Heart J (2003) 0.92

Saposins A, B, C, and D in plasma of patients with lysosomal storage disorders. Clin Chem (2000) 0.91

Relation of socio-economic status to impaired fasting glucose and Type 2 diabetes: findings based on a large population-based cross-sectional study in Tianjin, China. Diabet Med (2013) 0.91

Adenoviral gene therapy with catalase suppresses experimental optic neuritis. Arch Ophthalmol (1999) 0.90

Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscles. Role of endocardial endothelium. Circ Res (1991) 0.90

Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure. Br Heart J (1982) 0.89

Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol (1994) 0.89

Phospholipid membrane restructuring induced by saposin C: a topographic study using atomic force microscopy. FEBS Lett (2001) 0.89

Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol (1995) 0.89

Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol (1989) 0.89

Spatial and temporal analysis of human infection with avian influenza A(H7N9) virus in China, 2013. Euro Surveill (2013) 0.88

Faster time to peak tension and velocity of shortening in right versus left ventricular trabeculae and papillary muscles of dogs. Circ Res (1986) 0.88

A health perception score predicts cardiac events in patients with heart failure: results from the IMPRESS trial. J Card Fail (2001) 0.88

Improvement of endocardial and vascular endothelial function on myocardial performance by captopril treatment in postinfarct rat hearts. Circulation (1999) 0.86

The importance of microalbuminuria as a cardiovascular risk indicator: A review. Can J Cardiol (2002) 0.85

Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: surgeon's role in survival. Eur J Surg Oncol (2008) 0.85

Atrial tachycardia induces remodelling of muscarinic receptors and their coupled potassium currents in canine left atrial and pulmonary vein cardiomyocytes. Br J Pharmacol (2007) 0.85

Age- and gender-related changes in endothelin and catecholamine release, and in autonomic balance in response to head-up tilt. Clin Sci (Lond) (1997) 0.85

Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol (2000) 0.85

Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation (1998) 0.85

Prazosin and congestive heart failure: short- and long-term therapy. Am J Med (1981) 0.84

Captopril in congestive heart failure: improved left ventricular function with decreased metabolic cost. Am Heart J (1982) 0.84